Scarica l'app Stockscreener
4.92
0.40%
-0.02
Dopo l'orario di chiusura:
4.92
Precedente Chiudi:
$4.94
Aprire:
$4.89
Volume 24 ore:
349.74K
Relative Volume:
0.58
Capitalizzazione di mercato:
$288.08M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
93.89
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
+0.00%
1M Prestazione:
+9.58%
6M Prestazione:
+6.72%
1 anno Prestazione:
+29.47%
Intervallo 1D:
$4.84
$5.01
Intervallo di 1 settimana:
$4.84
$5.155
Portata 52W:
$3.79
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Confronta VNDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.92 | 288.08M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.18 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
662.62 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
613.04 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.54 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.59 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate - Marketscreener.com
Vanda Pharmaceuticals announces FDA review date for new drug By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals’ New Drug Application Accepted by FDA - TipRanks
Vanda Pharmaceuticals announces FDA review date for new drug - Investing.com
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
Insider Buying: Mihael Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
CLASS ACTION UPDATE for VNDA, CTL and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for AVEO, KHC and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for AVEO, DPLO and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock By Investing.com - Investing.com Australia
US FDA Spikes Vanda’s Hetlioz For Insomnia, Lack Of Well-Controlled Trial ‘Fatal’ - Citeline News & Insights
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos covered exercise/tax liability with 95,999 shares and bought $47,050 worth of shares (10,000 units at $4.71), decreasing direct ownership by 4% to 2,275,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for TYME, GE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Allspring Global Investments Holdings LLC Sells 77,738 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Purchases 10,000 Shares - MarketBeat
Vanda Pharmaceuticals CEO acquires $47,600 in common stock By Investing.com - Investing.com Australia
Vanda Pharmaceuticals CEO acquires $47,600 in common stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow
US High Growth Tech Stocks With Strong Potential - Yahoo Finance UK
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
February 2025 Penny Stocks To Keep An Eye On - Simply Wall St
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $47,650 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $47,650 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $47,650 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,341,730 units (SEC Form 4) - Quantisnow
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $44,640 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos purchases $44,640 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $44,640 worth of shares (10,000 units at $4.46), increasing direct ownership by 0.43% to 2,331,730 units (SEC Form 4) - Quantisnow
Vanda Falls Again As Teva, US FDA Win Judgment In Tasimelteon Approval Case - Citeline News & Insights
Vanda Pharmaceuticals CFO Kevin Moran purchases $8,778 in stock By Investing.com - Investing.com Nigeria
Vanda Pharmaceuticals develops ASO therapy for rare disease By Investing.com - Investing.com Australia
Vanda Pharmaceuticals CFO Kevin Moran purchases $8,778 in stock - Investing.com India
SVP, CFO & Treasurer Moran Kevin Patrick bought $8,779 worth of shares (2,000 units at $4.39), increasing direct ownership by 0.57% to 355,763 units (SEC Form 4) - Quantisnow
Vanda Pharmaceuticals develops ASO therapy for rare disease - Investing.com India
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vanda Pharmaceuticals Inc Azioni (VNDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 05 '25 |
Buy |
5.02 |
10,000 |
50,200 |
2,285,731 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 03 '25 |
Buy |
4.71 |
10,000 |
47,050 |
2,275,731 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 28 '25 |
Buy |
4.76 |
10,000 |
47,600 |
2,361,730 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 27 '25 |
Buy |
4.76 |
10,000 |
47,600 |
2,351,730 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 26 '25 |
Buy |
4.76 |
10,000 |
47,650 |
2,341,730 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 25 '25 |
Buy |
4.46 |
10,000 |
44,640 |
2,331,730 |
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Feb 21 '25 |
Buy |
4.39 |
2,000 |
8,779 |
355,763 |
| Mitchell Stephen Ray | Director |
Nov 14 '24 |
Sale |
5.17 |
5,000 |
25,863 |
44,857 |
0.22%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):